Coated tablet formulation and method
DC CAFCFirst Claim
1. A coated tablet comprising(a) a tablet core;
- (b) an inner seal coating layer coated on the tablet core wherein the inner seal coating layer comprises about 1 mg to about 100 mgs of a polyvinyl alcohol based formulation wherein the polyvinyl alcohol based formulation comprises polyvinyl alcohol;
(c) a second coating layer coated on the inner seal coating of the tablet core, wherein the second coating layer comprises about 0.2 mgs to about 140 mgs of saxagliptin, or a pharmaceutically acceptable salt thereof, and about 2 mgs to about 140 mgs of a polyvinyl alcohol based formulation wherein the polyvinyl alcohol based formulation comprises polyvinyl alcohol; and
(d) an outer protective coating layer coated on the second coating layer of the tablet core wherein the outer protective coating layer comprises about 1 mg to about 100 mgs of a polyvinyl alcohol based formulation wherein the polyvinyl alcohol based formulation comprises polyvinyl alcohol.
3 Assignments
Litigations
0 Petitions
Accused Products
Abstract
A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin
or its HCl salt,
which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
36 Citations
10 Claims
-
1. A coated tablet comprising
(a) a tablet core; -
(b) an inner seal coating layer coated on the tablet core wherein the inner seal coating layer comprises about 1 mg to about 100 mgs of a polyvinyl alcohol based formulation wherein the polyvinyl alcohol based formulation comprises polyvinyl alcohol; (c) a second coating layer coated on the inner seal coating of the tablet core, wherein the second coating layer comprises about 0.2 mgs to about 140 mgs of saxagliptin, or a pharmaceutically acceptable salt thereof, and about 2 mgs to about 140 mgs of a polyvinyl alcohol based formulation wherein the polyvinyl alcohol based formulation comprises polyvinyl alcohol; and (d) an outer protective coating layer coated on the second coating layer of the tablet core wherein the outer protective coating layer comprises about 1 mg to about 100 mgs of a polyvinyl alcohol based formulation wherein the polyvinyl alcohol based formulation comprises polyvinyl alcohol. - View Dependent Claims (2, 3, 4, 5, 10)
-
-
6. A coated tablet comprising:
-
a) a tablet core comprising about 49.5% lactose monohydrate, about 45% microcrystalline cellulose, about 5% croscarmellose sodium, and about 0.5% magnesium stearate; b) an inner seal coating layer coated on the tablet core, wherein the inner seal coating layer comprises about 40% polyvinyl alcohol, about 20% polyethylene glycol, about 15% talc, and about 25% titanium dioxide; c) a second coating layer coated on the inner seal coating of the tablet core, wherein the second coating layer comprises saxagliptin or a pharmaceutically acceptable salt thereof, polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide; and d) optionally an outer protective coating layer coated on the second coating layer of the tablet core, wherein the outer protective coating comprises polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide. - View Dependent Claims (7, 8, 9)
-
Specification